Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

A Study of CPI-0209 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04104776
Recruitment Status : Recruiting
First Posted : September 26, 2019
Last Update Posted : September 26, 2019
Information provided by (Responsible Party):
Constellation Pharmaceuticals

Brief Summary:
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors alone and in combination with other therapies. CPI-0209 is a small molecule inhibitor of EZH2.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Drug: CPI-0209 Drug: Irinotecan Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 252 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination With Other Therapy in Patients With Advanced Solid Tumors
Actual Study Start Date : September 18, 2019
Estimated Primary Completion Date : December 31, 2025
Estimated Study Completion Date : March 1, 2026

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Monotherapy
CPI-0209 will be dosed once per day orally in 28 day cycles
Drug: CPI-0209
CPI-0209 alone

Experimental: Combination Therapy
CPI-0209 will be dosed once per day orally in 21 day cycles. Irinotecan iv will be dosed on day 1 of every cycle.
Drug: CPI-0209
CPI-0209 alone

Drug: Irinotecan
CPI-0209 in combination with irinotecan

Primary Outcome Measures :
  1. Phase 1: Frequency of Dose-limiting toxicities (DLTs) [ Time Frame: DLTs assessed during Cycle 1 (first 28 days on study for monotherapy and first 21 days for combination therapy) ]
    The maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of CPI-0209 as monotherapy and in combination with irinotecan in patients with advanced solid tumors

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years or older
  • Life expectancy of ≥ 12 weeks
  • Recovered to baseline or Grade ≤ 1 severity from toxicity related to prior treatments, unless AEs are clinically non-significant and/or stable on supportive therapy
  • ECOG 0-1
  • Adequate bone marrow function
  • Adequate renal function
  • Adequate liver function

Exclusion Criteria:

  • Previous solid organ or hematopoietic cell transplant
  • Known brain metatstases
  • Known Gilbert's disease
  • Prior EZH2 inhibitor
  • Concomitant medication(s) or food or beverage that are moderate or strong CYP3A inducers or inhibitors within 2 weeks prior to the first dose of study drug
  • Clinically significant cardiovascular disease
  • Major surgery within 4 weeks
  • GI disorders affecting absorption
  • Uncontrolled infection
  • Suspected pneumonitis or interstitial lung disease
  • Known additional malignancy that is active and/or progressive requiring treatment
  • Known HIV or active hepatitis
  • Chronic liver disease
  • Women of child bearing potential and men with reproductive potential, if they are - unwilling to use adequate contraception while on study therapy and for 3 months thereafter
  • Patients unwilling or unable to comply with this study protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04104776

Layout table for location information
United States, Michigan
START Midwest Recruiting
Grand Rapids, Michigan, United States, 49546
Contact: Shannon S Skibinski-Preston, MPH    616-954-5552   
Contact: Yvette Cole, RN    616-389-1652   
Principal Investigator: Nehal Lakhani, MD         
United States, New Jersey
Hackensack University Medical Center Not yet recruiting
Hackensack, New Jersey, United States, 07601
Contact: Chelsea McCabe    551-996-4725   
Principal Investigator: Martin Gutierrez, MD         
United States, Texas
START San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Karla Rivas, RN    210-593-5943   
Contact: Carrie Choi, RN    210-593-2547   
Principal Investigator: Drew Rasco, MD         
Sponsors and Collaborators
Constellation Pharmaceuticals

Layout table for additonal information
Responsible Party: Constellation Pharmaceuticals Identifier: NCT04104776    
Other Study ID Numbers: 0209-01
First Posted: September 26, 2019    Key Record Dates
Last Update Posted: September 26, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents